Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88
Anti-MAG
Biological
Clinical
Electrophysiological
Haemopathy
MYD88
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
26
07
2023
accepted:
13
10
2023
revised:
10
10
2023
medline:
27
2
2024
pubmed:
18
11
2023
entrez:
18
11
2023
Statut:
ppublish
Résumé
Anti-MAG neuropathies are associated with an IgM monoclonal gammopathy of undetermined significance (MGUS) or with a malignant haemopathy. Our objective was to determine whether the presence of a haemopathy or somatic mutations of MYD88 and CXCR4 genes influences disease presentation and response to rituximab (RTX). We included 79 patients (mean age 74 years, disease duration 9.68 years) who had a bone marrow aspiration with morphologic and immunophenotypic analysis. MYD88 Malignant haematological disorders were discovered in 17 patients (22%): 13 Waldenstrom macroglobulinemia, 3 marginal zone lymphoma and one mantle cell lymphoma. MYD88 MYD88
Identifiants
pubmed: 37979093
doi: 10.1007/s00415-023-12068-4
pii: 10.1007/s00415-023-12068-4
doi:
Substances chimiques
CXCR4 protein, human
0
Immunoglobulin M
0
Myeloid Differentiation Factor 88
0
Receptors, CXCR4
0
MYD88 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1320-1330Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Svahn J, Petiot P, Antoine JC, Vial C, Delmont E, Viala K, Steck AJ, Magot A, Cauquil C, Zarea A, Echaniz-Laguna A, IancuFerfoglia R, Gueguen A, Magy L, Léger JM, Kuntzer T, Ferraud K, Lacour A, Camdessanché JP, Francophone Anti-MAG cohort Group (2018) Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry 89(5):499–505. https://doi.org/10.1136/jnnp-2017-316715
doi: 10.1136/jnnp-2017-316715
pubmed: 29070644
Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G (2000) Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 123(Pt 4):710–717. https://doi.org/10.1093/brain/123.4.710
doi: 10.1093/brain/123.4.710
pubmed: 10734002
Léger JM, Viala K, Nicolas G, Créange A, Vallat JM, Pouget J, Clavelou P, Vial C, Steck A, Musset L, Marin B, RIMAG Study Group (France and Switzerland) (2013) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80(24):2217–2225. https://doi.org/10.1212/WNL.0b013e318296e92b
doi: 10.1212/WNL.0b013e318296e92b
pubmed: 23667063
pmcid: 3721095
Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B (2009) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65(3):286–293. https://doi.org/10.1002/ana.21577
doi: 10.1002/ana.21577
pubmed: 19334068
Steck AJ (2021) Anti-MAG neuropathy: from biology to clinical management. J Neuroimmunol 361:577725. https://doi.org/10.1016/j.jneuroim.2021.577725
doi: 10.1016/j.jneuroim.2021.577725
pubmed: 34610502
Jimenez C, Sebastian E, Chillon MC, Giraldo P, Mariano Hernandez J, Escalante F et al (2013) MYD88 L265P is a marker highly characteristic of, but not restricted to. Waldenstrom’s Macroglobulinemia. Leukemia 27:1722–1728
doi: 10.1038/leu.2013.62
pubmed: 23446312
Landgren O (2021) Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events. Hematology 2021(1):662–672. https://doi.org/10.1182/hematology.2021000303.PMID:34889381;PMCID:PMC8791104
doi: 10.1182/hematology.2021000303.PMID:34889381;PMCID:PMC8791104
pubmed: 34889381
pmcid: 8791104
Jiménez C, Sebastián E, Chillón MC et al (2013) MYD88 L265P is a marker highly characteristic of, but not restricted to. Waldenström’s macroglobulinemia. Leukemia 27(8):1722–1728
doi: 10.1038/leu.2013.62
pubmed: 23446312
Castillo JJ, Moreno DF, Arbelaez MI, Hunter ZR, Treon SP (2019) CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: a systematic review. Expert Rev Hematol 12(10):873–881. https://doi.org/10.1080/17474086.2019.1649132
doi: 10.1080/17474086.2019.1649132
pubmed: 31343930
Landgren O, Tageja N (2014) MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström’s Macroglobulinemia. Leukemia 28(9):1799–1803. https://doi.org/10.1038/leu.2014.88
doi: 10.1038/leu.2014.88
pubmed: 24573383
Varettoni M, Zibellini S, Defrancesco I, Ferretti V, Rizzo E, Malcovati L et al (2017) Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. https://doi.org/10.3324/haematol.2017.172718
doi: 10.3324/haematol.2017.172718
pubmed: 28983055
pmcid: 5709107
Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst 15:185–195
doi: 10.1111/j.1529-8027.2010.00278.x
Athanasopoulos D, Motte J, Grüter T, Köse N, Yoon MS, Otto S, Schneider-Gold C, Gold R, Fisse AL, Pitarokoili K (2021) Evaluation of the EFNS/PNS diagnostic criteria in a cohort of CIDP patients. Ann Clin Transl Neurol 8(5):1110–1121. https://doi.org/10.1002/acn3.51357
doi: 10.1002/acn3.51357
pubmed: 33826247
pmcid: 8108415
Merkies IS, Schmitz PI, van der Meché FG, van Doorn PA (2000) Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 54(4):943–949. https://doi.org/10.1212/wnl.54.4.943
doi: 10.1212/wnl.54.4.943
pubmed: 10690990
Van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, Faber CG, Merkies IS (2011) Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76(4):337–345. https://doi.org/10.1212/WNL.0b013e318208824b
doi: 10.1212/WNL.0b013e318208824b
pubmed: 21263135
Graham RC, Hughes RA (2006) A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 77(8):973–976. https://doi.org/10.1136/jnnp.2005.081547
doi: 10.1136/jnnp.2005.081547
pubmed: 16574730
pmcid: 2077620
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A (2022) The 5th World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 36(7):1703–1719. https://doi.org/10.1038/s41375-022-01613-1
doi: 10.1038/s41375-022-01613-1
pubmed: 35732831
pmcid: 9252913
Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, Corso A, Orlandi E, Bonfichi M, Gotti M, Pascutto C, Mangiacavalli S, Croci G, Fiaccadori V, Morello L, Guerrera ML, Paulli M, Cazzola M (2013) Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood 121(13):2522–2528. https://doi.org/10.1182/blood-2012-09-457101
doi: 10.1182/blood-2012-09-457101
pubmed: 23355535
Feng R, Zhao J, Sun F, Miao M, Sun X, He J, Li Z (2022) Comparison of the deep immune profiling of B cell subsets between healthy adults and Sjögren’s syndrome. Ann Med 54(1):472–483. https://doi.org/10.1080/07853890.2022.2031272
doi: 10.1080/07853890.2022.2031272
pubmed: 35098838
pmcid: 8812739
Berrón-Ruíz L, López-Herrera G, Ávalos-Martínez CE, Valenzuela-Ponce C, Ramírez-San Juan E, Santoyo-Sánchez G, MújicaGuzmán F, Espinosa-Rosales FJ, Santos-Argumedo L (2016) Variations of B cell subpopulations in peripheral blood of healthy Mexican population according to age: relevance for diagnosis of primary immunodeficiencies. Allergol Immunopathol (Madr) 44(6):571–579. https://doi.org/10.1016/j.aller.2016.05.003
doi: 10.1016/j.aller.2016.05.003
pubmed: 27780620
Attarian S, Azulay JP, Boucraut J, Escande N, Pouget J (2001) Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies. Clin Neurophysiol 112(3):457–463. https://doi.org/10.1016/s1388-2457(01)00469-2
doi: 10.1016/s1388-2457(01)00469-2
pubmed: 11222967
Fatehi F, Delmont E, Grapperon AM, Salort-Campana E, Sévy A, Verschueren A, Boucraut J, Attarian S (2017) Motor unit number index (MUNIX) in patients with anti-MAG neuropathy. Clin Neurophysiol 128(7):1264–1269. https://doi.org/10.1016/j.clinph.2017.04.022
doi: 10.1016/j.clinph.2017.04.022
pubmed: 28545015
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, PATH Study Group (2018) Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 17(1):35–46. https://doi.org/10.1016/S1474-4422(17)30378-2
doi: 10.1016/S1474-4422(17)30378-2
pubmed: 29122523
Armstrong RA (2014) When to use the Bonferroni correction. Ophthalmic Physiol Opt 34(5):502–508. https://doi.org/10.1111/opo.12131
doi: 10.1111/opo.12131
pubmed: 24697967
Launay M, Delmont E, Benaim C, Sacconi S, Butori C, Desnuelle C (2009) Les polyneuropathies avec IgM monoclonale anti-MAG : étude descriptive clinique, biologique, électrophysiologique et anatomopathologique d’une cohorte de 13 patients [Anti-MAG paraproteinemic demyelinating polyneuropathy: a clinical, biological, electrophysiological and anatomopathological descriptive study of a 13-patients’ cohort]. Rev Neurol (Paris) 165(12):1071–1079. https://doi.org/10.1016/j.neurol.2009.04.008 . (French)
doi: 10.1016/j.neurol.2009.04.008
pubmed: 19487003
Chassande B, Léger JM, Younes-Chennouf AB, Bengoufa D, Maisonobe T, Bouche P et al (1998) Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 21:55–62
doi: 10.1002/(SICI)1097-4598(199801)21:1<55::AID-MUS8>3.0.CO;2-F
pubmed: 9427224
Tang MH, Mathis S, Duffau P, Cazenave P, Solé G, Duval F, Soulages A, Le Masson G (2020) Prognostic factor of poor outcome in anti-MAG neuropathy: clinical and electrophysiological analysis of a French Cohort. J Neurol 267(2):561–571. https://doi.org/10.1007/s00415-019-09618-0
doi: 10.1007/s00415-019-09618-0
pubmed: 31705291
Xu L, Hunter ZR, Yang G, Cao Y, Liu X, Manning R, Tripsas C, Chen J, Patterson CJ, Kluk M, Kanan S, Castillo J, Lindeman N, Treon SP (2014) Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia 28(8):1698–1704. https://doi.org/10.1038/leu.2014.65
doi: 10.1038/leu.2014.65
pubmed: 24509637
Castellani F, Visentin A, Schirinzi E, Salvalaggio A, Cacciavillani M, Candiotto C, Baratè C, Cellini A, Bertorelle R, Siciliano G, Trentin L, Briani C (2023) Mutational profile in 75 patients with anti-myelin-associated glycoprotein neuropathy: clinical and hematologic therapy response and hints on new therapeutic targets. Neurol Neuroimmunol Neuroinflamm 10(4):e200122. https://doi.org/10.1212/NXI.0000000000200122
doi: 10.1212/NXI.0000000000200122
pubmed: 37137530
pmcid: 10155778
Vinarkar S, Arora N, Chowdhury SS, Saha K, Pal B, Parihar M, Radhakrishnan VS, Chakrapani A, Bhartia S, Bhave S, Chandy M, Nair R, Mishra DK (2019) MYD88 and CXCR4 mutation profiling in lymphoplasmacytic lymphoma/Waldenstrom’s Macroglobulinaemia. Indian J Hematol Blood Transfus 35(1):57–65. https://doi.org/10.1007/s12288-018-0978-1
doi: 10.1007/s12288-018-0978-1
pubmed: 30828149
Jiménez C, Sebastián E, Chillón MC, Giraldo P, Mariano Hernández J, Escalante F, González-López TJ, Aguilera C, de Coca AG, Murillo I, Alcoceba M, Balanzategui A, Sarasquete ME, Corral R, Marín LA, Paiva B, Ocio EM, Gutiérrez NC, González M, San Miguel JF, García-Sanz R (2013) MYD88 L265P is a marker highly characteristic of, but not restricted to. Waldenström’s macroglobulinemia. Leukemia 27(8):1722–1728. https://doi.org/10.1038/leu.2013.62
doi: 10.1038/leu.2013.62
pubmed: 23446312
Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, Varettoni M, Brown JR, Tai YT, Anderson KC, Munshi NC, Patterson CJ, Manning RJ, Tripsas CK, Lindeman NI, Treon SP (2013) MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 121(11):2051–2058. https://doi.org/10.1182/blood-2012-09-454355
doi: 10.1182/blood-2012-09-454355
pubmed: 23321251
pmcid: 3596964
Vos JM, Notermans NC, D’Sa S, Lunn MP, van der Pol WL, Kraan W, Reilly MM, Chalker J, Gupta R, Kersten MJ, Pals ST, Minnema MC (2018) High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy. J Neurol Neurosurg Psychiatry 89(9):1007–1009. https://doi.org/10.1136/jnnp-2017-316689
doi: 10.1136/jnnp-2017-316689
pubmed: 29018161
Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, Mavrianou-Koutsoukou N, Liacos C, Patseas D, Kanellias N, Migkou M, Ziogas DC, Eleutherakis-Papaiakovou E, Roussou M, Fotiou D, Terpos E, Kastritis E, Dimopoulos MA (2018) Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. Leukemia 32(12):2617–2625. https://doi.org/10.1038/s41375-018-0197-7
doi: 10.1038/s41375-018-0197-7
pubmed: 30026568
pmcid: 6286389
Gazzola S, Delmont E, Franques J, Boucraut J, Salort-Campana E, Verschueren A, Sagui E, Hubert AM, Pouget J, Attarian S (2017) Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy. J Neurol Sci 15(377):144–148. https://doi.org/10.1016/j.jns.2017.04.015
doi: 10.1016/j.jns.2017.04.015
Niermeijer JM, Eurelings M, Lokhorst HL, van der Pol WL, Franssen H, Wokke JH, Notermans NC (2009) Rituximab for polyneuropathy with IgM monoclonal gammopathy. J Neurol Neurosurg Psychiatry 80(9):1036–1039. https://doi.org/10.1136/jnnp.2008.155325
doi: 10.1136/jnnp.2008.155325
pubmed: 19684235
Dalakas MC (2017) Rituximab in anti-MAG neuropathy: more evidence for efficacy and more predictive factors. J Neurol Sci 15(377):224–226. https://doi.org/10.1016/j.jns.2017.04.016
doi: 10.1016/j.jns.2017.04.016
Delmont E, Wang F, Lefaucheur JP, Puma A, Breniere C, Beaudonnet G, Cintas P, Collin R, Fortanier E, Grapperon AM, Jomir L, Kribich H, Kouton L, Kuntzer T, Lenglet T, Magot A, Nordine T, Ochsner F, Bolloy G, Pereon Y, Salort-Campana E, Tard C, Vicino A, Verschueren A, Attarian S (2020) Motor unit number index as an individual biomarker: reference limits of intra-individual variability over time in healthy subjects. Clin Neurophysiol 131(9):2209–2215. https://doi.org/10.1016/j.clinph.2020.06.019
doi: 10.1016/j.clinph.2020.06.019
pubmed: 32707479
Castillo JJ, Palomba ML, Advani R, Treon SP (2016) Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Ther Adv Hematol 7(4):179–186. https://doi.org/10.1177/2040620716654102
doi: 10.1177/2040620716654102
pubmed: 27493708
pmcid: 4959643
Roufarshbaf M, Javeri M, Akbari V, Matin PH, Farrokhi P, Sadeghi E, Heidari Z, Moghaddas A (2022) Efficacy and safety of ibrutinib in mantle cell lymphoma: a systematic review and meta-analysis. Daru 30(2):367–378. https://doi.org/10.1007/s40199-022-00444-w
doi: 10.1007/s40199-022-00444-w
pubmed: 36057010
pmcid: 9715897
Denlinger NM, Epperla N, William BM (2018) Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. Cancer Manag Res 27(10):615–624. https://doi.org/10.2147/CMAR.S133291
doi: 10.2147/CMAR.S133291
Yasuda H, Tomizawa Y, Harada S, Sasaki M, Komatsu N, Ando J, Hattori N, Ando M (2022) Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib. Heliyon 8(10):e10928. https://doi.org/10.1016/j.heliyon.2022.e10928
doi: 10.1016/j.heliyon.2022.e10928
pubmed: 36247137
pmcid: 9557899
Arustamyan M, Kibrik P, Hatipoglu D, Bungo B, Mentias A, Hill BT, Moudgil R (2022) The safety of Bruton’s tyrosine kinase inhibitors in B-cell malignancies: a systematic review. Eur J Haematol 109(6):696–710. https://doi.org/10.1111/ejh.13854
doi: 10.1111/ejh.13854
pubmed: 36030394
Briani C, Visentin A, Castellani F, Cacciavillani M, Trentin L (2022) The BCL2 inhibitor venetoclax plus rituximab is active in MYD88 wild-type polyneuropathy with anti-MAG antibodies. Neurol Neuroimmunol Neuroinflamm 9(4):e1181. https://doi.org/10.1212/NXI.0000000000001181
doi: 10.1212/NXI.0000000000001181
pubmed: 35798560
pmcid: 9128027